Latest News and Press Releases

The Phase 1 trial of IMGS-001-a novel dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function-is expanding to Ochsner MD Anderson Cancer Center.

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...

MOUNTAIN VIEW, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating...

WASHINGTON, April 16, 2025 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has launched a multi-site Phase 2 clinical trial in the U.S. for its Marburg vaccine candidate, administering doses to...

Vantage Biosciences, a clinical-stage biotechnology company advancing innovative therapies for diabetic eye diseases, announces first NPDR patient dosed.

First-ever use of Ebenbuild’s Twinhale technology  in idiopathic pulmonary fibrosis lung modelsTrial results published in Nature Communications Munich, Germany – April 9, 2025 -- Ebenbuild, a company...

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high...

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone,...

$171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in...

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights